Organon (OGN) Revenue & Revenue Breakdown
Organon Revenue Highlights
Latest Revenue (Y)
$6.26B
Latest Revenue (Q)
$1.58B
Main Geography (Y)
Europe and Canada
Organon Revenue by Period
Organon Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.26B | 1.44% |
| 2022-12-31 | $6.17B | -2.06% |
| 2021-12-31 | $6.30B | -22.13% |
| 2020-12-31 | $8.10B | 4.10% |
| 2019-12-31 | $7.78B | -20.46% |
| 2018-12-31 | $9.78B | - |
Organon generated $6.26B in revenue during NA 2023, up 1.44% compared to the previous quarter, and up 64.06% compared to the same period a year ago.
Organon Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $1.58B | -1.56% |
| 2024-06-30 | $1.61B | -0.92% |
| 2024-03-31 | $1.62B | 1.50% |
| 2023-12-31 | $1.60B | 5.20% |
| 2023-09-30 | $1.52B | -5.53% |
| 2023-06-30 | $1.61B | 4.55% |
| 2023-03-31 | $1.54B | 3.57% |
| 2022-12-31 | $1.49B | -3.38% |
| 2022-09-30 | $1.54B | -3.03% |
| 2022-06-30 | $1.58B | 1.15% |
| 2022-03-31 | $1.57B | -2.31% |
| 2021-12-31 | $1.60B | 0.25% |
| 2021-09-30 | $1.60B | 0.31% |
| 2021-06-30 | $1.59B | 5.91% |
| 2021-03-31 | $1.51B | -52.60% |
| 2020-12-31 | $3.18B | 96.96% |
| 2020-09-30 | $1.61B | 5.70% |
| 2020-06-30 | $1.53B | -14.27% |
| 2020-03-31 | $1.78B | - |
Organon generated $1.58B in revenue during Q3 2024, up -1.56% compared to the previous quarter, and up 98.38% compared to the same period a year ago.
Organon Revenue Breakdown
Organon Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Europe and Canada | $1.67B | $1.63B | $1.74B |
| CHINA | $864.00M | $917.00M | $933.00M |
| Asia Pacific and Japan | $1.13B | $1.14B | $1.17B |
| UNITED STATES | $1.48B | - | - |
| Other Countries | $154.00M | $151.00M | $233.00M |
| Latin America, Middle East, Russia and Africa | $965.00M | $895.00M | $841.00M |
Organon's latest annual revenue breakdown by geography, as of Dec 23: Europe and Canada (26.71%), UNITED STATES (23.60%), Asia Pacific and Japan (18.03%), Latin America, Middle East, Russia and Africa (15.41%), CHINA (13.80%), and Other Countries (2.46%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHINA | $212.00M | $206.00M | $203.00M | $202.00M | $234.00M | $225.00M | $196.00M | $241.00M | $244.00M | $236.00M | $240.00M | $252.00M | $236.00M | $205.00M |
| Latin America, Middle East, Russia And Africa | $243.00M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Europe And Canada | $436.00M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Asia Pacific and Japan | $260.00M | $287.00M | $260.00M | $284.00M | $261.00M | $324.00M | $255.00M | $283.00M | $291.00M | $314.00M | $299.00M | $287.00M | $309.00M | $285.00M |
| Other Countries | $33.00M | $34.00M | $32.00M | $32.00M | $41.00M | $49.00M | $22.00M | $48.00M | $40.00M | $43.00M | $43.00M | $67.00M | $51.00M | $-28.00M |
| UNITED STATES | $398.00M | $371.00M | $1.11B | $370.00M | - | - | - | - | - | - | - | - | - | - |
| Europe and Canada | - | $450.00M | $414.00M | $392.00M | $467.00M | $400.00M | $388.00M | $363.00M | $443.00M | $436.00M | $427.00M | $410.00M | $470.00M | $490.00M |
| Latin America, Middle East, Russia and Africa | - | $274.00M | $278.00M | $239.00M | $234.00M | $214.00M | $230.00M | $236.00M | $216.00M | $209.00M | $246.00M | $238.00M | $190.00M | $203.00M |
Organon's latest quarterly revenue breakdown by geography, as of Sep 24: Europe And Canada (27.56%), UNITED STATES (25.16%), Asia Pacific and Japan (16.43%), Latin America, Middle East, Russia And Africa (15.36%), CHINA (13.40%), and Other Countries (2.09%).
Organon Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JNJ | Johnson & Johnson | $85.15B | $22.47B |
| MRK | Merck | $60.12B | $16.66B |
| PFE | Pfizer | $58.50B | $17.70B |
| ABBV | AbbVie | $54.32B | $14.46B |
| NVS | Novartis | $46.66B | $11.83B |
| AZN | AstraZeneca | $45.81B | $12.68B |
| BMY | Bristol-Myers Squibb Company | $45.01B | $11.89B |
| SNY | Sanofi | $43.07B | $11.12B |
| LLY | Eli Lilly and Company | $34.12B | $11.44B |
| AMGN | Amgen | $28.19B | $8.50B |
| GILD | Gilead Sciences | $27.12B | $7.55B |
| BIIB | Biogen | $9.84B | $2.47B |
| OGN | Organon | $6.26B | $1.58B |